166 related articles for article (PubMed ID: 28042874)
21. Tetrandrine potentiates the hypoglycemic efficacy of berberine by inhibiting P-glycoprotein function.
Shan YQ; Zhu YP; Pang J; Wang YX; Song DQ; Kong WJ; Jiang JD
Biol Pharm Bull; 2013; 36(10):1562-9. PubMed ID: 23924821
[TBL] [Abstract][Full Text] [Related]
22. Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease.
Zhao L; Cang Z; Sun H; Nie X; Wang N; Lu Y
BMC Endocr Disord; 2017 Feb; 17(1):13. PubMed ID: 28241817
[TBL] [Abstract][Full Text] [Related]
23. Transforming berberine into its intestine-absorbable form by the gut microbiota.
Feng R; Shou JW; Zhao ZX; He CY; Ma C; Huang M; Fu J; Tan XS; Li XY; Wen BY; Chen X; Yang XY; Ren G; Lin Y; Chen Y; You XF; Wang Y; Jiang JD
Sci Rep; 2015 Jul; 5():12155. PubMed ID: 26174047
[TBL] [Abstract][Full Text] [Related]
24. Improvement of intestinal transport, absorption and anti-diabetic efficacy of berberine by using Gelucire44/14: In vitro, in situ and in vivo studies.
Sun J; Bao H; Peng Y; Zhang H; Sun Y; Qi J; Zhang H; Gao Y
Int J Pharm; 2018 Jun; 544(1):46-54. PubMed ID: 29654898
[TBL] [Abstract][Full Text] [Related]
25. Berberine improves intralipid-induced insulin resistance in murine.
Dong ZH; Lin HY; Chen FL; Che XQ; Bi WK; Shi SL; Wang J; Gao L; He Z; Zhao JJ
Acta Pharmacol Sin; 2021 May; 42(5):735-743. PubMed ID: 32770172
[TBL] [Abstract][Full Text] [Related]
26. Nanoemulsion improves hypoglycemic efficacy of berberine by overcoming its gastrointestinal challenge.
Xu HY; Liu CS; Huang CL; Chen L; Zheng YR; Huang SH; Long XY
Colloids Surf B Biointerfaces; 2019 Sep; 181():927-934. PubMed ID: 31382342
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics, excretion of 8-cetylberberine and its main metabolites in rat urine.
Hu Y; Fan S; Liao X; Chen C; Su L; Li X
J Pharm Biomed Anal; 2017 Jan; 132():195-206. PubMed ID: 27750103
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics in rats and tissue distribution in mouse of berberrubine by UPLC-MS/MS.
Wang X; Wang S; Ma J; Ye T; Lu M; Fan M; Deng M; Hu L; Gao Z
J Pharm Biomed Anal; 2015 Nov; 115():368-74. PubMed ID: 26279368
[TBL] [Abstract][Full Text] [Related]
29. Berberine treatment attenuates the palmitate-mediated inhibition of glucose uptake and consumption through increased 1,2,3-triacyl-sn-glycerol synthesis and accumulation in H9c2 cardiomyocytes.
Chang W; Chen L; Hatch GM
Biochim Biophys Acta; 2016 Apr; 1861(4):352-62. PubMed ID: 26774040
[TBL] [Abstract][Full Text] [Related]
30. Berberine promotes glucagon-like peptide-1 (7-36) amide secretion in streptozotocin-induced diabetic rats.
Lu SS; Yu YL; Zhu HJ; Liu XD; Liu L; Liu YW; Wang P; Xie L; Wang GJ
J Endocrinol; 2009 Feb; 200(2):159-65. PubMed ID: 18996945
[TBL] [Abstract][Full Text] [Related]
31. Berberine ameliorates glucocorticoid-induced hyperglycemia: an in vitro and in vivo study.
Gupta M; Rumman M; Singh B; Mahdi AA; Pandey S
Naunyn Schmiedebergs Arch Pharmacol; 2024 Mar; 397(3):1647-1658. PubMed ID: 37704773
[TBL] [Abstract][Full Text] [Related]
32. Isolation and identification of urinary metabolites of berberine in rats and humans.
Qiu F; Zhu Z; Kang N; Piao S; Qin G; Yao X
Drug Metab Dispos; 2008 Nov; 36(11):2159-65. PubMed ID: 18703644
[TBL] [Abstract][Full Text] [Related]
33. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action.
Turner N; Li JY; Gosby A; To SW; Cheng Z; Miyoshi H; Taketo MM; Cooney GJ; Kraegen EW; James DE; Hu LH; Li J; Ye JM
Diabetes; 2008 May; 57(5):1414-8. PubMed ID: 18285556
[TBL] [Abstract][Full Text] [Related]
34. Effects of berberine on the pharmacokinetics of losartan and its metabolite EXP3174 in rats and its mechanism.
Li H; Liu L; Xie L; Gan D; Jiang X
Pharm Biol; 2016 Dec; 54(12):2886-2894. PubMed ID: 27327872
[TBL] [Abstract][Full Text] [Related]
35. Differences in Metabolite Profiles of Dihydroberberine and Micellar Berberine in Caco-2 Cells and Humans-A Pilot Study.
Chang C; Roh YS; Du M; Kuo YC; Zhang Y; Hardy M; Gahler R; Solnier J
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891813
[TBL] [Abstract][Full Text] [Related]
36. Berberine reduces insulin resistance through protein kinase C-dependent up-regulation of insulin receptor expression.
Kong WJ; Zhang H; Song DQ; Xue R; Zhao W; Wei J; Wang YM; Shan N; Zhou ZX; Yang P; You XF; Li ZR; Si SY; Zhao LX; Pan HN; Jiang JD
Metabolism; 2009 Jan; 58(1):109-19. PubMed ID: 19059538
[TBL] [Abstract][Full Text] [Related]
37. MgAl monolayer hydrotalcite increases the hypoglycemic effect of berberine by enhancing its oral bioavailability.
Wang A; Yang W; Yang X; Mei X; Hu T; Liang R; Meng D; Yan D
Biomed Pharmacother; 2020 Jul; 127():110140. PubMed ID: 32380387
[TBL] [Abstract][Full Text] [Related]
38. Berberine improves free-fatty-acid-induced insulin resistance in L6 myotubes through inhibiting peroxisome proliferator-activated receptor gamma and fatty acid transferase expressions.
Chen Y; Li Y; Wang Y; Wen Y; Sun C
Metabolism; 2009 Dec; 58(12):1694-702. PubMed ID: 19767038
[TBL] [Abstract][Full Text] [Related]
39. Berberine decreases cholesterol levels in rats through multiple mechanisms, including inhibition of cholesterol absorption.
Wang Y; Yi X; Ghanam K; Zhang S; Zhao T; Zhu X
Metabolism; 2014 Sep; 63(9):1167-77. PubMed ID: 25002181
[TBL] [Abstract][Full Text] [Related]
40. Berberine-induced bioactive metabolites of the gut microbiota improve energy metabolism.
Wang Y; Shou JW; Li XY; Zhao ZX; Fu J; He CY; Feng R; Ma C; Wen BY; Guo F; Yang XY; Han YX; Wang LL; Tong Q; You XF; Lin Y; Kong WJ; Si SY; Jiang JD
Metabolism; 2017 May; 70():72-84. PubMed ID: 28403947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
